FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection By Ogkologos - October 2, 2025 287 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study MK-3475A-D77 Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma December 5, 2025 After Struggling With Chronic Illnesses Most of Her Life, This Author... June 21, 2021 Nurse With Terminal Breast Cancer Spends Her Days Caring For Pediatric... April 14, 2020 Off Target: Investigating the Abscopal Effect as a Treatment for Cancer January 28, 2020 Load more HOT NEWS How MRI add-ons could accelerate the development of new treatments Access to Cancer Medicines and Clinical Trials Show Stark Variations Across... Professor Ian Tomlinson: “Philanthropy is priceless to science” Study presents an AI-guided approach to target cancer antigens
